Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 3 boards, counting each seat separately. Longest: Arrowhead Pharmaceuticals Inc., 3 years.
Arrowhead Pharmaceuticals Inc.
Director
Protagonist Therapeutics Inc.
Director
Annexon Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | Protagonist Therapeutics Inc. | Option exercise | +9,000 | $16.54 | $148,860 |
| Jun 23, 2026 | Protagonist Therapeutics Inc. | Open-market sale | −9,000 | $117.94 | $1,061,460 |
| Jun 10, 2026 | Protagonist Therapeutics Inc. | Option exercise | +3,000 | $11.80 | $35,400 |
| Jun 10, 2026 | Protagonist Therapeutics Inc. | Option exercise | +6,000 | $16.54 | $99,240 |
| Jun 10, 2026 | Protagonist Therapeutics Inc. | Open-market sale | −9,000 | $107.68 | $969,120 |
| May 29, 2026 | Protagonist Therapeutics Inc. | Option exercise | +9,000 | $11.80 | $106,200 |
| May 29, 2026 | Protagonist Therapeutics Inc. | Open-market sale | −9,000 | $99.64 | $896,760 |
| Feb 6, 2026 | Protagonist Therapeutics Inc. | Option exercise | +20,000 | $8.31 | $166,200 |
| Feb 6, 2026 | Protagonist Therapeutics Inc. | Open-market sale | −20,000 | $83.68 | $1,673,600 |
| Jan 2, 2026 | Protagonist Therapeutics Inc. | Grant or award | +2,695 | — | — |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −2,416 | $66.66 | $161,051 |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −5,451 | $68.01 | $370,723 |
| Dec 19, 2025 | Arrowhead Pharmaceuticals Inc. | Open-market sale | −500 | $68.53 | $34,265 |
| Dec 16, 2025 | Arrowhead Pharmaceuticals Inc. | Grant or award | +7,819 | — | — |
| Oct 10, 2025 | Protagonist Therapeutics Inc. | Option exercise | +12,000 | $6.98 | $83,760 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.